Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Stevens

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Clinical Journal of the American Society of Nephrology : CJASN|December 12, 2025
Efficacy, Mechanisms and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled TrialVikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, et al.
Hypertension (Dallas, Tex. : 1979)|December 5, 2025
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled TrialVikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, et al.
Clinical Pharmacokinetics|February 15, 2021
Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney DiseaseAnnemarie B van der Aart-van der Beek, Jeroen V Koomen, Claire C J Dekkers, et al.
The European Respiratory Journal|November 3, 2022
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysisFajri Gafar, Roeland E Wasmann, Helen M McIlleron, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Clinical Journal of the American Society of Nephrology : CJASN|December 12, 2025
Efficacy, Mechanisms and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled TrialVikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, et al.
Hypertension (Dallas, Tex. : 1979)|December 5, 2025
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled TrialVikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn, et al.
Clinical Pharmacokinetics|February 15, 2021
Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney DiseaseAnnemarie B van der Aart-van der Beek, Jeroen V Koomen, Claire C J Dekkers, et al.
The European Respiratory Journal|November 3, 2022
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysisFajri Gafar, Roeland E Wasmann, Helen M McIlleron, et al.
Pageof 8